ArticleHuman vaccines & immunotherapeutics2023
Characteristics and economic burden of hospitalized patients with herpes zoster in China, before vaccination.
Article in Human vaccines & immunotherapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.
- A scoping review of models for predicting the risk of postherpetic neuralgia.Frontiers in medicine · 2025Pooled it
- Herpes zoster as a vaccine-preventable risk factor increases the risk of dementia: A nested case-control study in Chinese population.Human vaccines & immunotherapeutics · 2026Article
- Clinical and epidemiological characteristics of herpes zoster at a tertiary care center compared to population-based data: a ten-year retrospective cohort study.BMC infectious diseases · 2026Article
- A Multicenter Prospective Study to Develop a Prediction Model for Postherpetic Neuralgia Using Clinical and Laboratory Indicators.Pain and therapy · 2026Article
- Burden of herpes zoster and postherpetic neuralgia in Jinan, China: incidence, recurrence, and direct medical costs, 2018-2023, a population-based retrospective cohort study.BMC infectious diseases · 2026Article
- Unraveling immune-inflammation-aging network interactions: an interpretable machine learning model predicts the risk of postherpetic neuralgia.Frontiers in immunology · 2026Article
- Spatial-temporal dynamics of HZ prevalence among high-risk groups: a global multiregional cohort analysis since 1990.Virology journal · 2025Article
- Vaccination coverage, willingness and determinants of herpes zoster vaccine among individuals aged 50 and above in Ningbo, China: A population-based cross-sectional study.Human vaccines & immunotherapeutics · 2025Article
- A simple sonographic approach to thoracic transforaminal epidural injections for zoster-associated pain involving multiple nerves: an exploratory prospective cohort study.Korean journal of anesthesiology · 2025Article
- Development of a Prediction Model and Corresponding Scoring Table for Postherpetic Neuralgia Using Six Machine Learning Algorithms: A Retrospective Study.Pain and therapy · 2024Article
- Article
- The Burden of Herpes Zoster on Hospital Admissions: A Retrospective Analysis in the Years of 2015-2021 from the Abruzzo Region, Italy.Vaccines · 2024Article
- Analysis of Risk Factors and Development and Validation of a Dynamic Nomogram for Postherpetic Neuralgia: A Retrospective Study.Journal of pain research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Herpes zoster (HZ) brings a significant economic burden. The HZ vaccine was introduced in China for the first time in 2020, and there is a lack of up-to-date information on the hospitalization costs and characteristics prior to vaccination. This study aimed to describe the characteristics and economic burden of HZ inpatients in Hunan Province, China, and analyze the factors influencing the length of stay (LOS) and costs. This was a retrospective study and we extracted information from the Chinese National Health Statistics Network Reporting System on HZ inpatients in Hunan Province, China from 2017 to 2019. Spatial join tools and Global or Local Moran's Index were used for the geographic analysis of hospitalized HZ incidence. Multivariate linear regression models were used to analyze the factors influencing LOS and costs. There were 44,311 HZ inpatients included in this study, incurring a total of $31,857,734 medical costs. These patients had a median LOS of 8 days and a median expenditure of $573.47. Older age, more comorbidities, and the presence of complications with nervous system involved were all significantly associated with longer LOS and higher costs. HZ infection resulted in a large direct medical cost and heavy disease burden, especially in patients with advanced age or underlying medical conditions. The HZ vaccine has the potential to effectively reduce the disease burden and should be widely popularized especially among high-risk groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.